Selvita S.A. | Income Statement

Fiscal year is January-December. All values PLN Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
13,153.10
28,864.80
41,028.60
48,133.10
67,535.90
77,205.60
Cost of Goods Sold (COGS) incl. D&A
23,080.60
34,235.30
50,278.40
46,430.90
82,202.50
118,229.80
Gross Income
9,927.50
5,370.60
9,249.80
1,702.20
14,666.60
41,024.20
SG&A Expense
843.10
1,764.60
3,264.90
20,820.30
2,986.90
4,308.40
EBIT
10,989.30
7,420.10
12,911.30
7,577.70
10,898.10
46,195.30
Unusual Expense
40.10
-
-
130.10
46.30
20,787.30
Non Operating Income/Expense
8,718.10
12,888.60
15,150.90
7,193.50
21,791.60
33,339.20
Interest Expense
72.70
59.60
31.50
35.80
231.20
315.80
Pretax Income
2,366.80
5,427.10
2,820.90
266.30
10,682.50
8,985.70
Income Tax
18.60
423.00
3,412.10
3,968.10
2,868.40
8,093.30
Equity in Affiliates
-
-
-
1,016.50
1,082.20
-
Consolidated Net Income
2,385.40
5,850.10
6,233.00
2,685.40
6,731.90
892.50
Net Income
2,385.40
5,850.10
6,269.80
2,720.20
6,406.90
106.30
Net Income After Extraordinaries
2,385.40
5,850.10
6,269.80
2,720.20
6,406.90
106.30
Net Income Available to Common
2,385.40
5,850.10
6,269.80
2,720.20
6,406.90
106.30
EPS (Basic)
0.23
0.56
0.48
0.20
0.47
0.01
Basic Shares Outstanding
10,463.60
10,463.60
13,050.10
13,443.30
13,771.20
15,971.20
EPS (Diluted)
0.23
0.56
0.47
0.20
0.47
0.01
Diluted Shares Outstanding
10,463.60
10,463.60
13,229.70
13,739.30
13,771.20
15,522.70
EBITDA
8,906.80
5,065.70
9,478.60
3,960.30
5,658.00
37,970.20
Other Operating Expense
218.70
285.00
396.70
11,540.40
6,755.40
862.70
Non-Operating Interest Income
17.20
18.20
612.80
283.80
66.50
1,370.30
Minority Interest Expense
-
-
36.90
34.80
325.00
998.80

About Selvita

View Profile
Address
Park Life Science
Kraków MA 30
Poland
Employees -
Website http://www.selvita.com
Updated 07/08/2019
Selvita SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. It operates through the following segments: Innovation, Services, and Bioinformatics. The Innovation segment focuses on the small-molecule marketing activities of the pharmacological action, which is the next stage of the process of developing the commercialization process.